{
    "nct_id": "NCT06072586",
    "official_title": "A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (HGG) Participants with EGFR Alterations or Fusions Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration with PK-triggered Expansion Cohort",
    "inclusion_criteria": "* Participants who have had a prior resection of diagnosed HGG (2021 WHO grade 3 and 4), defined as participants who have progressed on or following standard therapy, which includes maximal surgical resection, temozolomide, and fractionated radiotherapy.\n* Adequate archival or biopsy tissue available for testing of EGFR alterations.\n* Participants must have measurable disease preoperatively.\n* Have a performance status (PS) of â‰¤2 on the Eastern Cooperative Oncology Group (ECOG) scale.\n* Ability to swallow oral medications.\n* Participant has adequate bone marrow and organ function\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pregnancy or breastfeeding.\n* Known allergic reactions to components of the BDTX-1535.\n* Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis, as determined by the investigator.\n* Known active systemic bacterial infection, fungal infection, or detectable viral infection .\n* Significant cardiovascular disease.\n* Symptomatic or radiographic leptomeningeal disease.\n* Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study .\n* Concurrent use of prohibited medications.",
    "miscellaneous_criteria": ""
}